Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

Published:2015-06-09 Issue:3 Volume:96 Page:285-290
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Gómez Montse¹,Guillem Vicent¹,Pereira Arturo²,Ferrer-Marín Francisca³,Álvarez-Larrán Alberto⁴,Kerguelen Ana⁵,Estrada Natàlia⁶,Martínez-López Joaquín⁷,Angona Anna⁴,Amat Paula¹,Navarro Blanca¹,Besses Carles⁴,Hernández-Boluda Juan-Carlos¹

Affiliation:

1. Hematology and Medical Oncology Department; Hospital Clínico Universitario; INCLIVA; Valencia Spain

2. Hemotherapy and Hemostasis Department; Hospital Clínic; Barcelona Spain

3. Hematology Department; Hospital Morales Messeguer; Murcia Spain

4. Hematology Department; Hospital del Mar-IMIM; Barcelona Spain

5. Hematology Department; Hospital La Paz; Madrid Spain

6. Hematology Department; Institut Català d'Oncologia-Hospital Germans Trias i Pujol; Badalona Spain

7. Hematology Department; Hospital 12 de Octubre; Madrid Spain

Funder

Fondo de InvestigacionesSanitarias

Spanish Ministry of Health

FundaciónEspañola de Hematología y Hemoterapia

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12588/fullpdf

Reference38 articles.

1. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders;Cervantes;Leukemia,2008

2. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study;Frederiksen;Blood,2011

3. Higher risk of primary cancers after polycythaemia vera and vice versa;Fallah;Br J Haematol,2011

4. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms;Vannucchi;Cancer Epidemiol Biomarkers Prev,2009

5. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group;Najean;Blood,1997

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precancerous skin lesions and malignant skin tumors associated with hydroxyurea treatment: Evaluation of a large series and review of the literature;TURKDERM;2022-12-31

2. Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide;eJHaem;2022-09-02

3. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis;Journal of the American Academy of Dermatology;2022-02

4. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea‐ and ruxolitinib‐pretreated patient with polycythaemia vera;Journal of the European Academy of Dermatology and Venereology;2021-12-02

5. A review of hydroxyurea-related cutaneous adverse events;Expert Opinion on Drug Safety;2021-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3